{"id":1640,"date":"2019-03-19T00:00:00","date_gmt":"2019-03-18T23:00:00","guid":{"rendered":"https:\/\/www.ship2b.org\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer"},"modified":"2025-02-08T01:11:53","modified_gmt":"2025-02-08T00:11:53","slug":"admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer","status":"publish","type":"post","link":"https:\/\/www.ship2b.org\/en\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/","title":{"rendered":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer"},"content":{"rendered":"

 <\/p>\n\n\n

BStartup de Banco Sabadell\u00a0 y Ship2B<\/a> han liderado una inversi\u00f3n de 200.000? en ADmit Therapeutics<\/a>, una startup<\/em> que actualmente desarrolla un test para la detecci\u00f3n precoz del Alzheimer. Ship2B ha participado a trav\u00e9s de Equity4Good, su veh\u00edculo de inversi\u00f3n coinvertido por el Fondo Europeo de Inversi\u00f3n su red de inversi\u00f3n de impacto. En la ronda tambi\u00e9n han participado G\u00e9nesis Biomed y otros inversores privados.<\/p>\n\n\n\n

ADmit Therapeutics destinar\u00e1 la inversi\u00f3n a acometer el plan de desarrollo de la prueba de diagn\u00f3stico, a iniciar la fase de validaci\u00f3n cl\u00ednica y a acuerdos con partners<\/em> comerciales. Se prev\u00e9 que la empresa desarrolle un nuevo dispositivo IVD de laboratorio que obtenga la correspondiente marca CE a finales de 2022.<\/p>\n\n\n\n

“Nuestro principal objetivo es desarrollar una prueba de diagn\u00f3stico precoz de Alzheimer e implementarla en la pr\u00e1ctica cl\u00ednica. A corto plazo el test de diagn\u00f3stico permitir\u00eda  optimizar el reclutamiento de los pacientes en los ensayos cl\u00ednicos, de tal manera que se incrementar\u00eda la posibilidad de identificar un f\u00e1rmaco curativo para esta enfermedad al poder demostrarse su eficacia? <\/strong>explica la Dra. Marta Barrachina, directora general y cofundadora de la empresa. Barrachina considera que los socios de ADmit Therapeutics son esenciales para avanzar en esta direcci\u00f3n: ?Esta ronda de inversi\u00f3n nos permite valorizar nuestra prueba de concepto cl\u00ednica, abri\u00e9ndonos las puertas a iniciar la validaci\u00f3n cl\u00ednica y reforzar nuestra propiedad intelectual<\/strong>“. Marta Barrachina es Doctora en Bioqu\u00edmica y MBA. Es la investigadora principal en IDIBELL desde del 2006, ha liderado proyectos competitivos p\u00fablicos y privados, y es la inventora de siete patentes. Los m\u00e9dicos Ramon Re\u00f1\u00e9 y Jordi Gasc\u00f3n son los otros cofundadores y act\u00faan como Consejo Asesor M\u00e9dico de la empresa liderando el estudio cl\u00ednico.<\/p>\n\n\n\n

La enfermedad de Alzheimer (AD) es una necesidad m\u00e9dica no cubierta. No existe un f\u00e1rmaco curativo dado que los ensayos cl\u00ednicos han presentado una tasa de \u00e9xito del 0,4%, la m\u00e1s baja de todas las enfermedades graves de gran prevalencia. Actualmente existe un infradiagn\u00f3stico de la enfermedad (sobretodo en la fase leve) y se acostumbra a realizar en la fase moderada con un retraso de entre 12 y 24 meses una vez han aparecido los s\u00edntomas. El problema radica en que la enfermedad presenta un periodo asintom\u00e1tico que puede durar hasta 20 a\u00f1os.<\/p>\n\n\n\n

\nhttps:\/\/ship2b.org\/tech4health\/\n<\/div><\/figure>\n\n\n\n

 <\/p>\n\n\n

 <\/p>","protected":false},"excerpt":{"rendered":"

  BStartup de Banco Sabadell\u00a0 y Ship2B han liderado una inversi\u00f3n de 200.000? en ADmit Therapeutics, una startup que actualmente desarrolla un test para la detecci\u00f3n precoz del Alzheimer. Ship2B ha participado a trav\u00e9s de Equity4Good, su veh\u00edculo de inversi\u00f3n coinvertido por el Fondo Europeo de Inversi\u00f3n su red de inversi\u00f3n de impacto. En la … Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":1641,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[23,27,191],"tags":[184,186,187],"class_list":["post-1640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inversion-de-impacto","category-aceleracion","category-salud-y-calidad-de-vida","tag-s2b-tech4social","tag-s2b-tech4health","tag-equity4good"],"acf":[],"yoast_head":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation\" \/>\n<meta property=\"og:description\" content=\"  BStartup de Banco Sabadell\u00a0 y Ship2B han liderado una inversi\u00f3n de 200.000? en ADmit Therapeutics, una startup que actualmente desarrolla un test para la detecci\u00f3n precoz del Alzheimer. Ship2B ha participado a trav\u00e9s de Equity4Good, su veh\u00edculo de inversi\u00f3n coinvertido por el Fondo Europeo de Inversi\u00f3n su red de inversi\u00f3n de impacto. En la … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Ship2B Foundation\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-18T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T00:11:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"monolitdigital\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"monolitdigital\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/\",\"url\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/\",\"name\":\"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.ship2b.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg\",\"datePublished\":\"2019-03-18T23:00:00+00:00\",\"dateModified\":\"2025-02-08T00:11:53+00:00\",\"author\":{\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage\",\"url\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg\",\"contentUrl\":\"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg\",\"width\":800,\"height\":400,\"caption\":\"BLOG_ADMIT\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.ship2b.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ship2b.org\/#website\",\"url\":\"https:\/\/www.ship2b.org\/\",\"name\":\"Ship2B Foundation\",\"description\":\"Adventurers for a better world\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ship2b.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb\",\"name\":\"monolitdigital\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g\",\"caption\":\"monolitdigital\"},\"url\":\"https:\/\/www.ship2b.org\/en\/actualidad\/author\/monolitdigital\/\"}]}<\/script>","yoast_head_json":{"title":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/","og_locale":"en_US","og_type":"article","og_title":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation","og_description":"  BStartup de Banco Sabadell\u00a0 y Ship2B han liderado una inversi\u00f3n de 200.000? en ADmit Therapeutics, una startup que actualmente desarrolla un test para la detecci\u00f3n precoz del Alzheimer. Ship2B ha participado a trav\u00e9s de Equity4Good, su veh\u00edculo de inversi\u00f3n coinvertido por el Fondo Europeo de Inversi\u00f3n su red de inversi\u00f3n de impacto. En la … Read more","og_url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/","og_site_name":"Ship2B Foundation","article_published_time":"2019-03-18T23:00:00+00:00","article_modified_time":"2025-02-08T00:11:53+00:00","og_image":[{"width":800,"height":400,"url":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg","type":"image\/jpeg"}],"author":"monolitdigital","twitter_card":"summary_large_image","twitter_misc":{"Written by":"monolitdigital","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/","url":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/","name":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer - Ship2B Foundation","isPartOf":{"@id":"https:\/\/www.ship2b.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg","datePublished":"2019-03-18T23:00:00+00:00","dateModified":"2025-02-08T00:11:53+00:00","author":{"@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb"},"breadcrumb":{"@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#primaryimage","url":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg","contentUrl":"https:\/\/www.ship2b.org\/wp-content\/uploads\/2020\/05\/BLOG_ADMIT.jpg","width":800,"height":400,"caption":"BLOG_ADMIT"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ship2b.org\/actualidad\/admit-therapeutics-cierra-una-ronda-de-200-000-e-para-seguir-desarrollando-un-test-para-la-deteccion-precoz-del-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.ship2b.org\/en\/"},{"@type":"ListItem","position":2,"name":"ADmit Therapeutics cierra una ronda de 200.000 ? para seguir desarrollando un test para la detecci\u00f3n precoz del Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/www.ship2b.org\/#website","url":"https:\/\/www.ship2b.org\/","name":"Ship2B Foundation","description":"Adventurers for a better world","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ship2b.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/5e1e3cfe72b47ae1bcbc7b9d714051bb","name":"monolitdigital","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ship2b.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/946a2b9f66f4160be08b4f9a06887503c98ef66c5b9b64ee89d92fc57ef7eb18?s=96&d=mm&r=g","caption":"monolitdigital"},"url":"https:\/\/www.ship2b.org\/en\/actualidad\/author\/monolitdigital\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/comments?post=1640"}],"version-history":[{"count":2,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1640\/revisions"}],"predecessor-version":[{"id":15104,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/posts\/1640\/revisions\/15104"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/media\/1641"}],"wp:attachment":[{"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/media?parent=1640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/categories?post=1640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ship2b.org\/en\/wp-json\/wp\/v2\/tags?post=1640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}